Andrew H. Ko

机构：University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center · ORCID：0000-0003-0426-1753

发表论文 303 篇 · 总被引 17936 次 · h-index 50

代表论文

• Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies (2025 · Nature Medicine · 被引 78)
• Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma (2024 · Nature Communications · 被引 13)
• Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer (2024 · Annals of Surgical Oncology · 被引 13)
• Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study (2025 · ESMO Gastrointestinal Oncology · 被引 12)
• Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/ II MORPHEUS Trial (2024 · Clinical Pharmacology & Therapeutics · 被引 6)
• Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies (2026 · Clinical Cancer Research · 被引 4)